Mindfulness May Sharpen Cognition in Neurological Disease, but Evidence Remains Fragile

Mindfulness meditation has traveled a remarkable distance from monastic practice to clinical prescription, and a new systematic review now asks whether that journey is justified for one of medicine’s most vulnerable populations: adults living with neurological disorders. In a meta-analysis published in BMC Nursing, a team of researchers led by Hui Yan of Zigong First People’s Hospital in China pooled data from randomized controlled trials to determine whether structured mindfulness-based interventions can genuinely improve cognitive function in patients whose brains have been compromised by stroke, mild cognitive impairment, and related conditions. The answer they arrived at is a study in scientific nuance: a promising signal, wrapped in layers of statistical uncertainty that the authors themselves are careful not to overstate.

The research team searched six electronic databases through April 25, 2025, applying the rigorous PRISMA reporting framework to identify randomized controlled trials that compared mindfulness-based interventions against control conditions in adults with diagnosed neurological disorders. The interventions in question were not vague invitations to relax. They included mindfulness-based cognitive therapy, known as MBCT, which blends meditative practice with elements of cognitive behavioral therapy; mindfulness-based stress reduction, or MBSR, the eight-week protocol pioneered for chronic pain and stress; and other structured programs such as mindful awareness practice and standalone mindfulness meditation. After screening, eight trials met the inclusion criteria, and 479 participants contributed data to the primary cognitive meta-analysis, a modest but not trivial evidence base for a question of this clinical importance.

The statistical machinery behind the analysis was deliberately conservative. Because the researchers anticipated substantial clinical and methodological diversity among the trials, they prespecified random-effects models, estimating between-study variance using restricted maximum likelihood and computing confidence intervals with the Hartung-Knapp adjustment, a method that widens intervals when the number of studies is small and guards against spuriously precise findings. Risk of bias in the individual trials was assessed with the Cochrane RoB 2 tool, the current standard for randomized trial appraisal, and the certainty of the accumulated evidence was graded using the GRADE framework. These choices matter, because in meta-analyses of behavioral interventions, the difference between an honest estimate and an inflated one often lies precisely in such methodological decisions.

The headline result is eye-catching on its face. Across the eight trials, mindfulness-based interventions were associated with higher cognitive scores on average, with a pooled effect size expressed as Hedges g of 0.82 and a 95 percent confidence interval running from 0.12 to 1.52, yielding a p-value of 0.027. For readers unaccustomed to effect size metrics, Hedges g expresses the difference between groups in standard deviation units, so a value of 0.82 would, if taken at face value, represent a large treatment effect, approaching the kind of improvement one might hope for from a dedicated cognitive rehabilitation program rather than a meditation course.

But the very next statistical findings temper that enthusiasm considerably. The heterogeneity statistic, I-squared, came in at a striking 90 percent, meaning that roughly nine-tenths of the variability in observed effects across trials reflects genuine differences between studies rather than chance. More telling still, the prediction interval, which estimates the range of effects a future trial might plausibly produce, stretched from minus 1.17 to 2.82, crossing the null value of zero. In practical terms, the analysis cannot rule out the possibility that a new trial of mindfulness in this population could find no benefit, or even a transient apparent harm. The authors accordingly rated the evidence as low certainty, concluding that mindfulness may be associated with higher cognitive scores but that confidence in this finding is limited.

Seeking to understand where the benefit might concentrate, the researchers conducted exploratory subgroup analyses across three dimensions: disease type, intervention model, and treatment duration. None reached statistical significance. The test for subgroup differences by disease type produced a p-value of 0.098, by intervention model a p-value of 0.154, and by treatment duration a p-value of 0.954, the last figure indicating that longer and shorter programs performed essentially indistinguishably in the available data. This absence of effect modification is itself informative. It suggests that the observed pooled effect is not being driven by any single recognizable clinical scenario, such as post-stroke cognitive impairment versus mild cognitive impairment, nor by a particular branded protocol, leaving the true sources of heterogeneity unexplained.

The secondary outcomes tell an equally measured story. Depression, often a co-traveling symptom in neurological illness and a frequent target of mindfulness programs, did not differ significantly between intervention and control groups across seven trials encompassing 443 participants, with a pooled effect of g equal to minus 0.19 and a confidence interval spanning from minus 1.08 to 0.71. Dispositional mindfulness, the psychological trait that these interventions are explicitly designed to cultivate, did show a small but statistically robust positive pooled estimate of g equal to 0.17 across two trials with 118 participants, with a tight confidence interval of 0.04 to 0.30. In other words, the programs reliably made participants more mindful, even as the downstream cognitive and mood benefits remained statistically elusive in the pooled data.

One trial, involving 80 participants, reported scores on the National Institutes of Health Stroke Scale, a clinician-rated measure of neurological impairment. Because only a single eligible trial contributed this outcome, the authors declined to meta-analyze it, but the reported mean difference of minus 2.89 points, with a confidence interval of minus 3.60 to minus 2.18, hints at a potentially meaningful reduction in stroke-related impairment. A single trial, however, no matter how encouraging, cannot anchor a clinical recommendation, and the review team correctly resisted the temptation to fold this orphan result into broader claims.

The authors’ conclusion is refreshingly candid for a field often criticized for enthusiasm outrunning evidence. Low-certainty evidence, they write, suggests that mindfulness-based interventions may be associated with higher cognitive scores in adults with neurological disorders, but substantial heterogeneity and a prediction interval crossing the null limit confidence in the finding, and further well-designed trials are needed before such programs can be recommended specifically for cognitive improvement. The research received no specific grant funding, and the authors declared no competing interests, facts that lend additional credibility to their restrained interpretation.

For clinicians and patients, the practical takeaway is one of cautious openness rather than prescription. Mindfulness-based programs are inexpensive, low-risk, and increasingly embedded in rehabilitation and nursing care, and this analysis does nothing to suggest they cause harm. What it does suggest is that the cognitive benefits reported in small randomized trials may be real, may be inflated by publication and design biases, or may vary dramatically depending on patient population, protocol fidelity, and outcome measurement. Until larger, better-standardized randomized controlled trials accumulate, mindfulness in neurological care remains best framed as a promising adjunct whose cognitive dividends are still awaiting definitive proof, a conclusion that is, in its own way, the most scientifically honest result this review could have delivered.

Subject of Research: Effects of mindfulness-based interventions on cognitive outcomes in adults with neurological disorders

Article Title: Effects of mindfulness-based interventions on cognitive outcomes in adults with neurological disorders: a systematic review and meta-analysis of randomized controlled trials

Article References: Yan, H., Zhong, Y., Ji, Q., Zhu, F., Yin, S., & Liu, Y. (2026). Effects of mindfulness-based interventions on cognitive outcomes in adults with neurological disorders: a systematic review and meta-analysis of randomized controlled trials. BMC Nursing. https://doi.org/10.1186/s12912-026-05359-4

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05359-4

Keywords: mindfulness, meta-analysis, neurological disorders, cognitive function, stroke, mild cognitive impairment, mindfulness-based cognitive therapy, mindfulness-based stress reduction, randomized controlled trials, systematic review, depression, rehabilitation